Current Studies
Neovascular Age-Related Macular Degeneration (nAMD or Wet AMD)
Ocular SOL-R / OTX-TKI-2023-AMD-303 / Ocular Therapeutix, Inc.
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration (nAMD). Study Details – ClinicalTrials.gov
Daybreak / KS301P109 / Kodiak Sciences, Inc.
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD). Study Details – ClinicalTrials.gov
Protocol AO / DRCR Retina Network / Jaeb Center for Health Research
Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD. Study Details – ClinicalTrials.gov
Geographic Atrophy (GA)
Archer II / ANX007-GA-02 / Annexon, Inc.
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA). Study Details – ClinicalTrials.gov
Active Studies – Not Currently Enrolling
Neovascular Age-Related Macular Degeneration (nAMD or Wet AMD)
Ocular SOL / OTX-TKI-2023-AMD-301 / Ocular Therapeutix, Inc.
A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration (nAMD). Study Details – ClinicalTrials.gov
For more information on our research studies, please contact Rebecca Ottosen or complete the form found here.
